Is the impact of management measurable in cystic fibrosis?;L'impact de la prise en charge de la mucoviscidose est-il mesurable?

Archives de Pediatrie

Volumn 7, Issue SUPPL. 2, 2000, Pages 349-351

  Navarro, J ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; MUCOLYTIC AGENT;

CONFERENCE PAPER; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; GENE THERAPY; HUMAN; LUNG FUNCTION TEST; OUTCOMES RESEARCH; PALLIATIVE THERAPY; PREVALENCE; RISK FACTOR; SURVIVAL;

EID: 0033814786     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(00)88829-6     Document Type: Conference Paper

References (10)

1. Rault G, Guillond-Bataille M, Feingold J. Registres : vers l'harmonisation et l'exhaustivite. In : Reference Mucoviscidose. Paris : Elsevier ; 1997. p. 14-8.
2. Rault G, Grosskopf C. Vers un rapprochement des registres et observatoires de la mucovisidose. In : Référence Mucoviscidose, Paris : Elsevier ; 1998. p. 9-14.
3. Delaisi B, Grosskopf C, Regnault E, Goehrs JM, Navarro J. Registre international sur la mucoviscidose : comparaison des donnees françaises avec les données européennes pour 1995. Arch Pediatr 1998 ; 5 : 384-8.
4. Navarro J. Les registres épidémiologiques de la mucoviscidose : pour quoi faire ? In : Référence Mucoviscidose. Paris : Elsevier ; 1998. p. 3-4.
5. Navarro J, Rainisio M, Harms HK, Hodson M, Koch C, Mastella G et al. What are the factors affecting pulmonary function? 22th European CF conference. Berlin ; 1998.
6. Koch C, Me Kenzie S, Kaplowitz H, Hodson ME, Harms HK, Navarro J et al. International practice patterns by age and secerity of lung disease in cystic fibrosis. Data from the epidemiological registry of cystic fibrosis. Pediatr Pulmonol 1997 ; 24 : 15-23.
7. Koch C, Rainisio N, Harms HK, Hosdon ME, Mastella G, Mc Kenzie et al. Risk factors of importance for long term surviva of patients with cystic fibrosis. Neth J Med 1999 ; Suppl 1 : 23.
8. Frederiksen B. Improved survival in the Danish Cebter treated cystic fibrosis patients; results of aggressive treatment. Pediatr Pulmonol 1996 ; 21 : 153-8.
9. Harms HK, Navarro J, Hodson ME, Koch C, Mastella G, Rettig S et al. What differences existe between countries and centers. The epidemiologic registry of cystic fibrosis (ERCF). 22th European CF conference. Berlin ; 1998.
10. Merelle ME, Meerman TE, Dankert-Roelse JE. The influence of treatment at a specialized centre on the course of the disease of patients with cystic fibrosis. In: Travert G, eds. Neonatal screening for cystic fibrosis. Caen : Presses Universitaires de Caen ; 1999. p. 301-8.